Cara therapeutics, inc. (CARA)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13
Revenue:
Total revenue

8,093

4,511

5,785

5,208

4,382

-

5,062

2,874

-

0

0

0

911

0

0

79

7

0

2,440

874

489

914

1,125

960

178

973

1,018

9,973

0

Operating expenses:
Research and development

33,536

29,864

35,992

24,356

23,608

22,799

22,303

17,002

13,427

11,576

9,151

6,961

20,836

20,276

9,671

10,760

8,546

7,568

5,584

4,684

3,385

3,459

6,208

3,200

2,201

1,978

3,764

2,021

922

General and administrative

4,558

4,617

4,226

4,994

3,908

4,711

3,227

3,685

3,697

2,995

3,805

2,672

2,400

2,039

2,102

2,645

2,447

2,161

1,865

1,922

1,822

1,791

1,520

1,472

1,398

1,100

795

1,033

588

Total operating expenses

38,094

34,481

40,218

29,350

27,516

27,510

25,530

20,687

17,124

14,571

12,956

9,633

23,236

22,315

11,773

13,405

10,993

9,729

7,449

6,606

5,207

5,250

7,728

4,672

3,599

3,078

4,559

3,054

1,510

Operating loss

-30,001

-29,970

-34,433

-24,142

-23,134

-21,977

-20,468

-17,813

-17,124

-14,571

-12,956

-9,633

-22,325

-22,315

-11,773

-13,326

-10,986

-9,729

-5,009

-5,732

-4,718

-4,336

-6,603

-3,712

-3,421

-2,105

-3,541

6,919

-1,510

Other income, net

957

1,193

1,261

947

1,089

1,200

1,002

467

311

368

367

331

90

155

176

172

149

52

22

13

14

22

26

56

22

9

-1,034

-1,602

-1,129

Loss before benefit from income taxes

-29,044

-28,777

-33,172

-23,195

-22,045

-20,777

-19,466

-17,346

-16,813

-14,203

-12,589

-9,302

-22,235

-22,160

-11,597

-13,154

-10,837

-9,677

-4,987

-5,719

-4,704

-4,314

-6,577

-3,656

-3,399

-2,096

-4,575

5,317

-2,639

Benefit from income taxes

-122

-166

-330

-235

-85

-125

-66

-152

-46

-26

-145

-2

-31

-189

-55

-79

-145

-147

-200

-35

-15

-142

-32

-11

-16

-3

0

-20

-7

Net loss

-28,922

-28,611

-32,842

-22,960

-21,960

-20,652

-19,400

-17,194

-16,767

-14,177

-12,444

-9,300

-22,204

-21,971

-11,542

-13,075

-10,692

-9,530

-4,787

-5,684

-4,689

-4,172

-6,545

-3,645

-3,383

-2,093

-4,575

5,337

-2,632

Basic and Diluted

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-4,575

-

-1,741

Net loss per share:
Basic and Diluted

-0.62

-0.61

-0.74

-0.58

-0.56

-0.52

-0.51

-0.52

-0.51

-0.38

-0.38

-0.29

-0.81

-0.81

-0.42

-0.48

-0.39

-0.35

-0.19

-0.25

-0.21

-0.18

-0.29

-0.16

-0.22

-

-1.07

-

-0.48

Net (loss) income available to common stockholders - Basic

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,468

-

Net (loss) income available to common stockholders - Diluted

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

5,337

-

(Loss) income per share available to common stockholders - Basic

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0.34

-

(Loss) income per share available to common stockholders - Diluted

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0.33

-

Weighted average shares:
Basic and Diluted

46,724

46,789

44,517

39,818

39,552

39,539

38,034

33,315

32,681

32,680

32,591

32,239

27,299

27,290

27,282

27,282

27,259

27,299

25,545

22,828

22,808

22,888

22,713

22,608

15,654

-

4,288

-

3,659

Other comprehensive income (loss), net of tax of $0:
Change in unrealized gains (losses) on available-for-sale marketable securities

-238

17

-12

92

187

-127

70

57

-44

-110

53

-37

21

-17

-21

37

39

-

-

-

-

-

-

-

-

-

-

-

-

Total comprehensive loss

-29,160

-28,594

-32,854

-22,868

-21,773

-20,779

-19,330

-17,137

-16,811

-14,287

-12,391

-9,337

-22,183

-21,988

-11,563

-13,038

-10,653

-9,565

-4,787

-5,684

-4,689

-

-

-

-

-

-

-

-

Basic

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

4,288

-

Diluted

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

15,972

-

License and Milestone Fees [Member]
Total revenue

8,021

4,511

5,785

5,208

4,242

-

5,029

2,874

-

0

0

0

530

-

-

-

-

-

1,710

-

-

-

-

302

-

-

0

9,637

-

Collaborative Revenue [Member]
Total revenue

-

-

-

-

-

-

-

-

-

0

0

0

313

-

-

-

-

0

730

874

489

399

1,125

526

151

871

1,018

336

0

Clinical Compound Revenue [Member]
Total revenue

72

0

0

0

140

-

33

-

-

0

0

0

68

0

0

79

7

-

-

-

-

515

0

132

27

-

-

-

-